Capital Fund Management S.A. Acquires 17,007 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR)

Capital Fund Management S.A. lifted its stake in Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 33.9% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 67,135 shares of the company's stock after acquiring an additional 17,007 shares during the period. Capital Fund Management S.A. owned 0.12% of Structure Therapeutics worth $1,821,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Principal Financial Group Inc. increased its position in Structure Therapeutics by 45.1% in the 4th quarter. Principal Financial Group Inc. now owns 791,134 shares of the company's stock valued at $21,456,000 after buying an additional 245,775 shares in the last quarter. Franklin Resources Inc. raised its holdings in shares of Structure Therapeutics by 4.5% during the fourth quarter. Franklin Resources Inc. now owns 738,090 shares of the company's stock valued at $20,017,000 after purchasing an additional 31,984 shares during the last quarter. American Century Companies Inc. boosted its holdings in Structure Therapeutics by 12.3% in the 4th quarter. American Century Companies Inc. now owns 612,616 shares of the company's stock worth $16,614,000 after buying an additional 67,325 shares during the period. Invesco Ltd. lifted its stake in shares of Structure Therapeutics by 4.1% in the 4th quarter. Invesco Ltd. now owns 371,767 shares of the company's stock valued at $10,082,000 after purchasing an additional 14,559 shares during the last quarter. Finally, Candriam S.C.A. grew its holdings in Structure Therapeutics by 59.6% during the 4th quarter. Candriam S.C.A. now owns 215,421 shares of the company's stock worth $5,842,000 after acquiring an additional 80,421 shares in the last quarter. Institutional investors own 91.78% of the company's stock.

Structure Therapeutics Stock Up 9.0 %

NASDAQ GPCR traded up $1.95 during trading on Monday, reaching $23.71. 471,014 shares of the stock traded hands, compared to its average volume of 899,642. Structure Therapeutics Inc. has a fifty-two week low of $13.22 and a fifty-two week high of $62.74. The stock's 50-day moving average price is $20.23 and its 200 day moving average price is $28.31. The firm has a market cap of $1.36 billion, a price-to-earnings ratio of -32.13 and a beta of -1.35.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.23) by $0.01. Analysts anticipate that Structure Therapeutics Inc. will post -0.82 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have issued reports on the stock. Stifel Nicolaus began coverage on shares of Structure Therapeutics in a report on Wednesday, January 8th. They set a "buy" rating and a $50.00 price objective on the stock. William Blair assumed coverage on Structure Therapeutics in a report on Friday, February 28th. They issued an "outperform" rating for the company. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $81.29.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.